v2.4.0.6
Business Combinations - Additional Information (Detail) (USD $)
3 Months Ended 6 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended 6 Months Ended
Mar. 30, 2013
Mar. 24, 2012
Mar. 30, 2013
Mar. 24, 2012
Jan. 03, 2013
Mar. 30, 2013
Property, plant and equipment [Member]
Mar. 30, 2013
Land and buildings [Member]
Dec. 31, 2012
Chindex Medical Limited [Member]
Aug. 01, 2012
Gen-Probe Incorporated [Member]
Mar. 30, 2013
Gen-Probe Incorporated [Member]
Jan. 31, 2013
Gen-Probe Incorporated [Member]
Oct. 31, 2012
Gen-Probe Incorporated [Member]
Mar. 30, 2013
Gen-Probe Incorporated [Member]
Minimum [Member]
Mar. 30, 2013
Gen-Probe Incorporated [Member]
Maximum [Member]
Mar. 30, 2013
Gen-Probe Incorporated [Member]
Developed technology [Member]
Mar. 30, 2013
Gen-Probe Incorporated [Member]
Customer contract [Member]
Mar. 30, 2013
Gen-Probe Incorporated [Member]
Trade names [Member]
Business Acquisition [Line Items]                                  
Cash paid per share                 $ 82.75                
Amount paid to shareholders                 $ 3,800,000,000                
Amount paid to equity award holders                 169,000,000                
Net debt obtained by the Company to finance the acquisition                 3,480,000,000                
Direct transaction costs incurred                 34,300,000                
Remaining fair value of stock options assumed to be recognized as compensation expense                   23,200,000              
Vesting period                   3 years 6 months              
Risk free interest rate 0.50% 0.70% 0.50% 0.70%           0.41%              
Expected volatility                   39.90%              
Expected life                   3 years 7 months 6 days              
Dividend yield, rate                   0.00%              
Weighted average fair value of stock options, per share                   $ 7.07              
Adjustment to valuation of intangibles                   2,000,000              
Agreement to sell LIFECODES business to Immucor         85,000,000                        
Contingent payment of an additional amount based on future revenue results         10,000,000                        
Gain on the sale of LIFECODES business 900,000   900,000                            
Assets held-for-sale                   2,200,000              
Property and equipment 600,000   600,000                            
Discount rate used for cash flow projections                         10.00% 12.00%      
In-process Research and Development expense                   227,000,000              
In-process research and development, value                     27,000,000 7,000,000          
Total cost of completion of IPR&D projects                   46,000,000              
Discount rate                   12.00%              
Expected number of years for project completion                   4 years              
Finite-lived intangible assets, estimated useful life, years                             12 years 6 months 13 years 11 years
Fair value adjustment to increase the carrying amount           107,900,000 70,600,000                    
Net purchase price               $ 4,500,000 $ 3,972,176,000